Opin vísindi

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis

Title: Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
Author: Robson, Joanna C.
Dawson, Jill
Cronholm, Peter F.
Ashdown, Susan
Easley, Ebony
Kellom, Katherine S.
Gebhart, Don
Lanier, Georgia
Milman, Nataliya
Peck, Jacqueline
... 4 more authors Show all authors
Date: 2017-11-09
Language: English
Scope: 675-682
University/Institute: Háskóli Íslands
University of Iceland
School: Heilbrigðisvísindasvið (HÍ)
School of Health Sciences (UI)
Department: Læknadeild (HÍ)
Faculty of Medicine (UI)
Series: Rheumatology International;38(4)
ISSN: 0172-8172
1437-160X (eISSN)
DOI: 10.1007/s00296-017-3855-6
Subject: ANCA-associated vasculitis; Glucocorticoids; Patient perspectives; Granulomatosis with polyangiitis; Eosinophilic granulomatosis with polyangiitis; Microscopic polyangiitis; Æðasjúkdómar; Æðabólgur; Sjúklingar; Heilsufar; Eigindlegar rannsóknir
URI: https://hdl.handle.net/20.500.11815/697

Show full item record


Robson, J. C., Dawson, J., Cronholm, P. F., Ashdown, S., Easley, E., Kellom, K. S., . . . Merkel, P. A. (2018). Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology International, 38(4), 675-682. doi:10.1007/s00296-017-3855-6


Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA) are multisystem diseases of small blood vessels, collectively known as the anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). This study explores the patient’s perspective on the use of glucocorticoids, which are still a mainstay of treatment in AAV. Patients with AAV from the UK, USA, and Canada were interviewed, using purposive sampling to include a range of disease manifestations and demographics. The project steering committee, including patient partners, designed the interview prompts and cues about AAV, its treatment, and impact on health-related quality of life. Interviews were transcribed and analysed to establish themes grounded in the data. A treatment-related code was used to focus analysis of salient themes related to glucocorticoid therapy. Fifty interviews were conducted. Individual themes related to therapy with glucocorticoids emerged from the data and were analysed. Three overarching themes emerged: (1) Glucocorticoids are effective at the time of diagnosis and during relapse, and withdrawal can potentiate a flare, (2) glucocorticoids are associated with salient emotional, physical, and social effects (depression, anxiety, irritation, weight gain and change in appearance, diabetes mellitus, effect on family and work); and (3) patient perceptions of balancing the risks and benefits of glucocorticoids. Patients identified the positive aspects of treatment with glucocorticoids; they are fast-acting and effective, but, they voiced concerns about adverse effects and the uncertainty of the dose-reduction process. These results may be informative in the development of novel glucocorticoid-sparing regimens.


This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Files in this item

This item appears in the following Collection(s)